Forty-seven clinical isolates of methicillin-resistant Staphylococcus aureus (MRSA), collected between 1986 and 1990 from 29 institutions, were analyzed for susceptibility to various antibiotics. Twenty-six strains were homogeneously methicillin resistant (i.e., . 10% of the cells in these strains were able to grow on MuellerHinton agar containing 50 ,ug of methicillin per ml). The MICs of gentamicin, clindamycin, trimethoprimsulfamethoxazole, methicillin, and imipenem for homogeneous MRSA strains were higher than those for heterogeneously resistant strains. Both types of strains were, for the most part, susceptible to vancomycin and trimethoprim-sulfamethoxazole. Ciprofloxacin-resistant MRSA strains were not isolated prior to 1988 but made up 40% of the post-1987 strains. The level of methicillin resistance correlated well with the imipenem MIC, suggesting that susceptibility to imipenem may serve as a marker to identify and monitor the prevalence of homogeneous MRSA strains.
other semisynthetic penicillins were introduced during the 1960s, staphylococcal infections again appeared to be treatable. However, in the 1970s and 1980s, methicillin-resistant S. aureus (MRSA) strains emerged. MRSA strains account for 10% of S. aureus in large teaching hospitals, 6% in nonteaching hospitals, and 4.6% in small teaching hospitals (12) . Their prevalence was noted in a survey of 137 Veterans Administration hospitals, where MRSA strains were present in 3 centers in 1975 but in 111 in 1984 (15) . In this study, we observed that recent clinical MRSA strains have evolved again, this time to increased methicillin resistance.
Most of the clinical MRSA strains thus far examined are heterogeneously methicillin resistant (19) . In other words, usually 1 in 104 to 107 CFU can grow at high methicillin concentrations. Naturally occurring, homogeneously MRSA strains (in which the cells of the strain are uniform in their expression of methicillin resistance) are considered uncommon (2, 8, 9) . However, our study suggests that homogeneous MRSA strains are no longer scarce; a high proportion of MRSA strains isolated during 1986 to 1990 were homogeneously methicillin resistant.
Forty-seven MRSA isolates were collected from 29 different hospitals throughout the United States that were involved in the cefepime clinical trials ( for 48 h. EOP was defined as the CFU on 50-,ug/ml methicillin plates divided by the CFU on drug-free plates. A strain was considered heterogeneously methicillin resistant if the EOP was less than 0.1, and homogeneous when the EOP was between 0.1 and 1 (4) .
Of the 47 MRSA strains, 26 (55%) grew well on plates containing 50 ,ug of methicillin per ml; they were homogeneously methicillin resistant (Table 1) . For all 26, the methicillin MICs were -50 ,ug/ml, while for 22 the methicillin MICs were .200 ,ug/ml (see Table 4 ). The homogeneously methicillin-resistant strains were isolated throughout the 4-year period and represented MRSA strains from 15 centers ( Table 1) .
The antibiotic susceptibilities of these strains were determined (Table 2) . Vancomycin was the only drug active against all 47 isolates. TMP-SMX was also active, with only one isolate being resistant. The relatively uniform activities of vancomycin and TMP-SMX against MRSA strains have been reported by others (16, 18) .
Although ciprofloxacin was active against all 18 MRSA isolates collected between 1986 and 1987, 40% of the post-1987 MRSA strains were resistant to ciprofloxacin (Table 2) . These 12 ciprofloxacin-resistant strains represented isolates from 10 of 20 institutions that submitted MRSA strains between 1988 and 1990. Since the introduction of ciprofloxacin in late 1987, MRSA strains have rapidly developed resistance to this drug. Ciprofloxacin-resistant MRSAs increased from 15 to 48% during a 6-month period at one hospital (10) and from 10 to 92% during the first year of ciprofloxacin usage in another (16) .
No correlation existed between ciprofloxacin resistance and homogeneity in methicillin resistance. As previously stated, 10 homogeneous MRSA strains were isolated prior to 1988 (Table 1) , compared with no ciprofloxacin-resistant strains isolated during that same period ( Table 2 ). Of the 12 ciprofloxacin-resistant MRSA strains, 9 were homogeneously methicillin resistant.
A correlation between EOP and imipenem MICs was observed (Table 3) . Homogeneous strains, with EOP of 0.1 to 1.0, generally had imipenem MICs above 2 ,ug/ml. Heterogeneous MRSA strains, with EOP of i0-' to 10-5, had imipenem MICs of 0.25 to 1 ,ug/ml, while those with EOP of less than 10-5 had imipenem MICs of 0.13 ,ug/ml or less. This observation suggests that imipenem MICs may serve as an epidemiological marker which could identify shifts in or the degree of methicillin resistance in nosocomial MRSA isolates. Moreover, these data indicate that the wide range of 0.1 to 50 ,ug/ml for imipenem MICs reported for 90% of the MRSA strains studied may be due to the diverse collections of strains compiled for testing (5) .
Although heterogeneous MRSA strains may be susceptible to imipenem in vitro (Table 3) , this may not be predictive of a positive clinical response, since imipenem-resistant variants are readily isolated from some imipenem-susceptible strains (7) . MRSA strains with imipenem MICs of <0.75 ,ug/ml have been found to have increased imipenem MICs (to 32 ,ug/ml) and methicillin MICs (by 20-fold) when preincubated with 0.05 ,ug of imipenem per ml (7). Preincubation with methicillin, on the other hand, did not induce increased resistance to either drug (7) .
Homogeneous MRSA strains were generally less susceptible to antibiotics than heterogeneous methicillin-resistant strains (Table 4) . While 96% of the homogeneous strains had imipenem MICs greater than 2 ,ug/ml, none of the heterogeneous strains did. Similarly, 65% of homogeneous methicillin-resistant strains had TMP-SMX MICs of -0.4 and 7.6 ,ug/ml versus 5% of heterogeneous isolates. Also, 65% of homogeneous MRSA strains had gentamicin MICs of .16 Factors that determine the heterogeneous or homogeneous nature of methicillin resistance in S. aureus have not been fully elucidated. Methicillin resistance is the result of a unique low-affinity penicillin-binding protein, 2a or 2' (PBP2a), encoded by the chromosomal mec gene, absent in methicillin-susceptible strains (11, 22, 23) . Several genetic determinants encoded on the ,3-lactamase plasmid and on the bacterial chromosome appear to influence the level of methicillin resistance. The plasmid-encoded 1-lactamase repressor negatively controls the mec gene (6) . Thus, a heterogeneous MRSA cured of its f-lactamase plasmid, constitutively produces PBP2a and is homogeneously methicillin resistant. Such clinical P-lactamase-negative, homogeneous MRSA strains have been isolated (2) . The homogeneous strains in our study, however, still contained the 13-lactamase plasmid; 46 of the 47 strains produced 1-lactamase. Many were also resistant to mercury and cadmium, which are frequent markers of the penicillinase plasmid (14) . Of the 47 MRSA strains, 62% were resistant to mercury and 74% were resistant to cadmium. Of the 27 homogeneous MRSA strains, 54% were resistant to mercury and/or cadmium.
At least two chromosomal determinants are involved in the level of methicillin resistance. The first is mecR, which has been mapped to a site 1 kb upstream of the mec gene (20) . The presence of mecR represses PBP2a production, resulting in increased heterogeneity of methicillin resistance.
The second is femA (1) . FemA is a 48-kDa protein which is essential for enhanced methicillin resistance. FemA does not influence PBP2a production. A third possible determinant is femB, which is linked to femA (1). These and/or another chromosome-encoded determinant(s) may be responsible for the increased expression of methicillin resistance observed in our homogeneous MRSA strains. Studies are under way to characterize these homogeneously methicillin-resistant isolates further.
Prior to this report, strains reported in three recent studies (2, 9, 21) indicate that homogeneous MRSA strains may be found clinically. In the study by Boyce and Medeiros (2) We thank Michael Pucci for helpful discussions.
